{"organizations": [], "uuid": "5f1fd8d38573a29b8beb3258dd369b4814896ec7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/04/pr-newswire-gc-pharma-reports-full-year-2017-results.html", "country": "US", "domain_rank": 767, "title": "GC Pharma Reports Full Year 2017 Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-05T05:46:00.000+02:00", "replies_count": 0, "uuid": "5f1fd8d38573a29b8beb3258dd369b4814896ec7"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/04/pr-newswire-gc-pharma-reports-full-year-2017-results.html", "ord_in_thread": 0, "title": "GC Pharma Reports Full Year 2017 Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "south korea", "sentiment": "none"}, {"name": "yongin", "sentiment": "none"}], "organizations": [{"name": "gc pharma", "sentiment": "negative"}, {"name": "green cross corporati", "sentiment": "negative"}, {"name": "krw", "sentiment": "none"}, {"name": "ec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "YONGIN, South Korea, Feb. 4, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2017.\nKey Figures\nFull Year 2017\nGrowth (1)\nTotal revenues\nKRW 1,287.9 billion\n+7.5%\nOperating income\nKRW 90.3 billion\n15.1%\nK-IFRS net income\nKRW 56.7 billion\n(13%)\n(1) Results and percentages to the full financial year 2016\nFinancial Highlights\nDelivered total revenues growth of 7.5% to KRW 1.29 trillion (2016: KRW 1.20 trillion), driven mainly by plasma products and vaccines sales. Operating income increased 15.1% to KRW 90.3 billion (2016: KRW 78.5 billion), primarily due to higher revenue from plasma and vaccine products and 1.3% lower SG&A expense rate.\nProduct and Pipeline Highlights\nExpanded commercial portfolio with 7 new product launches. Progressed pipeline of innovative therapies with over 10 programs in Phase 3.\nEC Huh, Ph.D., GC Pharma President, commented:\n\"Our business performance again created significant value for shareholders and other stakeholders. To continue delivering on our promise to patients, we further strengthened our future growth opportunities in 2018 and expect to generate fairly strong top-line growth.\"\nAbout GC Pharma\nGC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.\nThis release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma's management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.\nView original content with multimedia: http://www.prnewswire.com/news-releases/gc-pharma-reports-full-year-2017-results-300593182.html\nSOURCE GC Pharma", "external_links": ["http://www.prnewswire.com/news-releases/gc-pharma-reports-full-year-2017-results-300593182.html"], "published": "2018-02-05T05:46:00.000+02:00", "crawled": "2018-02-05T05:19:44.008+02:00", "highlightTitle": ""}